Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial-Reference-Cited by-同舟云学术

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Published:2011-07 Issue:7 Volume:12 Page:642-653
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Adams Richard A,Meade Angela M,Seymour Matthew T,Wilson Richard H,Madi Ayman,Fisher David,Kenny Sarah L,Kay Edward,Hodgkinson Elizabeth,Pope Malcolm,Rogers Penny,Wasan Harpreet,Falk Stephen,Gollins Simon,Hickish Tamas,Bessell Eric M,Propper David,Kennedy M John,Kaplan Richard,Maughan Timothy S

Publisher

Elsevier BV

Subject

Oncology

Reference21 articles.

1. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial;Seymour;Lancet,2007

2. Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863);Beex;Eur J Cancer,2006

3. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer;Gennari;J Clin Oncol,2006

4. Intermittent androgen deprivation therapy for prostate cancer;Rashid;Oncologist,2004

5. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial;Maughan;Lancet,2003

Cited by 219 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT;Health Technology Assessment;2024-08

2. Therapeutic strategies targeting the epidermal growth factor receptor signaling pathway in metastatic colorectal cancer;World Journal of Gastrointestinal Oncology;2024-06-15

3. Optimising oncology drug expenditure in Ireland;Irish Journal of Medical Science (1971 -);2024-04-03

4. Do older patients with colorectal cancer experience more deterioration in health-related quality of life than younger patients during the first year of palliative chemotherapy? A prospective real-world observational study;Journal of Geriatric Oncology;2024-04

5. Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab in BRAFV600E-Mutant Metastatic Colorectal Cancer: The Preliminary Data from a Single-Center Observational Study;Medicina;2023-12-01